BlackRock’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $672M | Buy |
17,352,646
+1,307,632
| +8% | +$45.8M | 0.01% | 999 |
|
|
2026
Q1 | $618M | Buy |
16,045,014
+3,070,423
| +24% | +$113M | 0.01% | 956 |
|
|
2025
Q4 | $461M | Buy |
12,974,591
+2,605,056
| +25% | +$73.2M | 0.01% | 1165 |
|
|
2025
Q3 | $149M | Buy |
10,369,535
+1,742,954
| +20% | +$20.6M | ﹤0.01% | 1843 |
|
|
2025
Q2 | $61.9M | Buy |
8,626,581
+451,054
| +6% | +$2.5M | ﹤0.01% | 2331 |
|
|
2025
Q1 | $49M | Sell |
8,175,527
-163,695
| -2% | -$1.28M | ﹤0.01% | 2383 |
|
|
2024
Q4 | $65M | Buy |
8,339,222
+347,635
| +4% | +$3.46M | ﹤0.01% | 2304 |
|
|
2024
Q3 | $86.3M | Buy |
7,991,587
+703,209
| +10% | +$6.85M | ﹤0.01% | 2171 |
|
|
2024
Q2 | $61.4M | Buy |
7,288,378
+598,760
| +9% | +$4.54M | ﹤0.01% | 2298 |
|
|
2024
Q1 | $45M | Sell |
6,689,618
-65,966
| -1% | -$408K | ﹤0.01% | 2497 |
|
|
2023
Q4 | $39.7M | Buy |
6,755,584
+608,506
| +10% | +$4.66M | ﹤0.01% | 2624 |
|
|
2023
Q3 | $59.9M | Buy |
6,147,078
+669,416
| +12% | +$7.94M | ﹤0.01% | 2299 |
|
|
2023
Q2 | $64.9M | Buy |
5,477,662
+435,592
| +9% | +$5M | ﹤0.01% | 2323 |
|
|
2023
Q1 | $54.4M | Buy |
5,042,070
+95,627
| +2% | +$1.22M | ﹤0.01% | 2386 |
|
|
2022
Q4 | $57.2M | Buy |
4,946,443
+350,140
| +8% | +$4.34M | ﹤0.01% | 2369 |
|
|
2022
Q3 | $68.6M | Buy |
4,596,303
+1,299,523
| +39% | +$17.8M | ﹤0.01% | 2219 |
|
|
2022
Q2 | $29.7M | Buy |
3,296,780
+657,409
| +25% | +$4.49M | ﹤0.01% | 2860 |
|
|
2022
Q1 | $19.8M | Sell |
2,639,371
-59,283
| -2% | -$413K | ﹤0.01% | 3183 |
|
|
2021
Q4 | $23.2M | Sell |
2,698,654
-33,581
| -1% | -$292K | ﹤0.01% | 3182 |
|
|
2021
Q3 | $23M | Buy |
2,732,235
+54,847
| +2% | +$420K | ﹤0.01% | 3190 |
|
|
2021
Q2 | $21.7M | Buy |
2,677,388
+2,109,352
| +371% | +$17.8M | ﹤0.01% | 3246 |
|
|
2021
Q1 | $4.99M | Sell |
568,036
-22,093
| -4% | -$213K | ﹤0.01% | 3942 |
|
|
2020
Q4 | $6.63M | Buy |
590,129
+500,038
| +555% | +$5.49M | ﹤0.01% | 3573 |
|
|
2020
Q3 | $843K | Sell |
90,091
-17,057
| -16% | -$178K | ﹤0.01% | 4152 |
|
|
2020
Q2 | $197K | Sell |
107,148
-10,136
| -9% | -$18.8K | ﹤0.01% | 4372 |
|
|
2020
Q1 | $194K | Sell |
117,284
-5,688
| -5% | -$15.8K | ﹤0.01% | 4237 |
|
|
2019
Q4 | $355K | Sell |
122,972
-36,819
| -23% | -$150K | ﹤0.01% | 4223 |
|
|
2019
Q3 | $920K | Sell |
159,791
-3,659
| -2% | -$29.7K | ﹤0.01% | 4008 |
|
|
2019
Q2 | $1.71M | Sell |
163,450
-210,153
| -56% | -$2.8M | ﹤0.01% | 3829 |
|
|
2019
Q1 | $6.56M | Sell |
373,603
-9,002
| -2% | -$154K | ﹤0.01% | 3313 |
|
|
2018
Q4 | $6.73M | Buy |
382,605
+282,316
| +282% | +$8.35M | ﹤0.01% | 3282 |
|
|
2018
Q3 | $4.13M | Sell |
100,289
-11,271
| -10% | -$635K | ﹤0.01% | 3556 |
|
|
2018
Q2 | $6.4M | Buy |
+111,560
| New | +$5.36M | ﹤0.01% | 3435 |
|
Other funds holding COGT
JT
FFM
DM
TCM
BlackRock's COGT Position: Q2 2026 in Review
BlackRock increased its Cogent Biosciences (COGT) stake by 8.1% in Q2 2026, buying an estimated $45.8M and bringing the position to 17,352,646 shares worth $672M. The position accounts for 0.01% of the portfolio, ranked #999.
BlackRock first reported a position in COGT in Q2 2018 and has held it in 33 quarters since. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.
- BlackRock held 17,352,646 shares of Cogent Biosciences worth $672M as of Q2 2026.
- BlackRock bought 1,307,632 Cogent Biosciences shares in Q2 2026, an estimated $45.8M.
- Cogent Biosciences made up 0.01% of BlackRock's portfolio in Q2 2026, its #999 holding.
- BlackRock first reported a position in Cogent Biosciences in Q2 2018 and has held it in 33 quarters since.
- 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.